MindBio Therapeutics is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions.

They invest in clinical research to discover potential new treatment options and we aim to create novel medicines and treatment regimes from breakthrough microdosing studies.  

Phase I clinical trials are underway at the Medical and Health Sciences School of Pharmacy at the University of Auckland in New Zealand to determine the effectiveness of microdosing Lysergic Acid Diethylamide (LSD) for treating depression.

Phase 2 clinical trials have just been approved for microdosing of LSD in late stage cancer patients.  This study will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted – Meaning Centred Psychotherapy to standard Meaning-Centred Psychotherapy in people who have advanced cancer and anxiety or depression. Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. Our findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.

Recent News

Get the MindBio
Investor’s Kit now.


Market Cap